Olanzapine in the treatment of behavioral problems associated with autism: An open-label trial in Kuwait

Medical Principles and Practice

Volumn 17, Issue 5, 2008, Pages 415-418

  Fido, Abdullahi ^a   Al Saad, Samira ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b Kuwait Autism Center   (Kuwait)

Author keywords

Atypical antipsychotic agent; Autism; Clinical trial; Kuwait; Olanzapine

Indexed keywords

GLUCOSE; LIVER ENZYME; OLANZAPINE;

ADOLESCENT; ARTICLE; AUTISM; BLOOD CHEMISTRY; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISRUPTIVE BEHAVIOR; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; GLUCOSE BLOOD LEVEL; HEMATOLOGY; HUMAN; KUWAIT; LABORATORY TEST; MALE; PHYSICAL EXAMINATION; SEDATION; SIDE EFFECT; THORAX RADIOGRAPHY; URINALYSIS; WEIGHT CHANGE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; BENZODIAZEPINES; CHILD; HUMANS; KUWAIT; MALE; MENTAL DISORDERS; PROSPECTIVE STUDIES; PSYCHOLOGICAL TESTS; PSYCHOMETRICS;

EID: 49449095339     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000141508     Document Type: Article

References (28)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 2002.
2. Frombonne E: Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord 2003;33:365-382.
3. The Annual Statistical Abstract. Kuwait Autism Society 2006;2:51-58.
4. Bailey A, Lecouteur A, Gottesman J: Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995;25:63-77.
5. Piven J, Palmer P, Jacobi D: The broader autism phenotype: evidence from a family study of multiple-incidence autism families. Am J Psychiatry 1997;154:185-190.
6. Sykes NH, Lamb JS: Autism: the quest for the genes. Expert Rev Mol Med 2007;9:1-15.
7. Whitely P: A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism 1999;3:45-65.
8. Murch S: Diet, immunity, and autistic spectrum disorders. J Pediatr 2005;146:582-584.
9. Janusonis S: Statistical distribution of blood serotonin as a predictor of early autistic brain abnormalties. Theor Biol Med Model 2007;19:2-27.
10. Fido A, Dashti H, Al-Saad S: Biological correlates of childhood autism: 'trace elements'. Trace Elem Electrol 2002;19:1-4.
11. Fido A, Al-Saad S: Toxic trace elements in the hair of children with autism. Autism 2005;9:290-298.
12. Dosman CF, Brian JA, Drmic IE: Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol 2007;36:152-158.
13. Adams JB, Romdalvik J, Ramanujam VM: Mercury, lead, and zinc in baby teeth of children with autism versus controls. J Toxicol Environ Health 2007;70:1046-1051.
14. Horner RH, Carr EG, Strain PS: Problem behavior interventions for young children with autism: a research synthesis. J Autism Dev Disord 2002;32:423-446.
15. Hagopian LP, Pruzek JL, Bowman LG: Assessment and treatment of problem behavior occasioned by interruption of free-operant behavior. J Appl Behav Anal 2007;40:89-103.
16. Jerome J, Frantino E, Sturmey P: The effects of errorless learning and backward chaining on the acquisition of internet skills in adults with developmental disabilities. J Appl Behav Anal 2007;40:185-189.
17. Posey DJ, McDougle CJ: The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2000;8:45-63.
18. Aman MG: Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Semin Pediatr Neurol 2004;11:225-228.
19. Malone R, Maislin G, Choudhury M: Risperidone treatment in children and adolescents with autism: short-and long-term safety and effectiveness. Am Acad Child Adolesc Psychiatry 2002;41:140-147.
20. McCracken J, Mcgough J, Shah B: Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321.
21. Padina GJ, Bossie CA, Yousef E: Risperidone improves symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Autism Dev Disord 2007;37:367-373.
22. West L, Waldrop J: Risperidone use in the treatment of behavioral symptoms in children with autism. Pediatr Nursing 2006;32:550-555.
23. Potenza MN, Holmes JP, Kanes SJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
24. Malone R, Cater J, Sheikh R: Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Child Adolesc 2001;40:887-894.
25. Kemner C, Willemsen S, Sophie H: Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002;22:455-460.
26. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
27. Aman MG, Singh NN, Stewart AW: The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89:485-491.
28. Hollander E, Wasserman S, Swanson EN: A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006;16:541-548.